Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.
Sarah Williams, PhD, Senior Scientist, Metrion Biosciences
This talk was presented by Dr Sarah Williams at the Axol Metrion Interactive Stem Cell Forum held in May 2018. This project received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 Research and Innovation Program.
Please contact us if you would like any further information regarding our cardiac translational assays.
Applications of human iPSC derived cardiomyocytes
Human induced pluripotent stem cell derived cardiomyocytes (iPSC CM) can be differentiated from healthy or diseased donors.
Many applications of iPSC CM including:
To successfully utilise iPSC CM as a model system they need thorough functional characterisation.
Presented at the SPS meeting in September 2024, Dr Steve Jenkinson presents Metrion’s human induced pluripotent stem cell (hiPSC)-derived cardiomyocyte assay, an advanced tool, providing key advantages, for early cardiac derisking in drug discovery.
Presentation by Marc Rogers, CSO Metrion Biosciences, Nanion technologies Exhibitor session, 2020 Biophysical Society meeting, San Diego USA.